Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Commercialization deals
Biotech
Royalty bestows Zenas with $300M for autoimmune approval push
Royalty is paying Zenas $75 million upfront, with similar payments coming if obexelimab succeeds in phase 3 and secures FDA approval.
Darren Incorvaia
Sep 2, 2025 11:07am
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
Dec 4, 2024 11:55am
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 7:00am
Coya taps familiar friend Dr. Reddy's to commercialize ALS med
Dec 6, 2023 11:20am
Santhera offloads North American rights for DMD med to Catalyst
Jun 20, 2023 9:53am
Ascensia Diabetes Care launches Eversense's 6-month CGM system
Apr 4, 2022 10:45am
